Advancing Non-Surgical and Disease-Modifying Strategies: An Analysis of Therapeutic Gaps in the Global Primary Osteoarthritis Market
The Primary Osteoarthritis Market addresses the most common form of arthritis, a chronic, progressive degenerative joint disorder leading to pain, stiffness, and disability, predominantly affecting the knees, hips, and hands. The market is huge and consistently growing, fueled by the accelerating aging of the global population and the rising prevalence of obesity, both major risk factors for the disease. Current treatment modalities are largely symptomatic, including pharmacological interventions (NSAIDs, analgesics) to manage pain, non-pharmacological methods (physical therapy, weight management), and, for end-stage disease, surgical joint replacement. The market is constrained by a significant unmet need for Disease-Modifying Osteoarthritis Drugs (DMOADs), which are therapies capable of slowing, halting, or reversing the structural joint damage. The continued failure of numerous DMOAD candidates in clinical trials represents the primary obstacle to market innovation. For group discussion, it…